51. Scleroderma Clinical trials / Disease details
Clinical trials : 523 / Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00946699 (ClinicalTrials.gov) | March 2010 | 23/7/2009 | A Study of the Safety and Tolerability of MEDI-551 in Scleroderma | A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma | Scleroderma | Biological: MEDI-551;Biological: Placebo;Other: Placebo | MedImmune LLC | NULL | Completed | 18 Years | N/A | Both | 50 | Phase 1 | United States;Canada;United Kingdom |